• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Canadian Pacific Lymphoma Treatments

Treatment

There are fortunately a variety of treatments for lymphoma. These include radiation therapy and chemotherapy. The majority of chemotherapy is performed in a clinic, Canadian Pacific Lymphoma but some patients might need to remain overnight in the hospital. Radiation therapy is a non-invasive procedure that targets cancer cells in the body with high-energy radiation. The majority of types of radiation therapy require only a few visits to a doctor over the course of several weeks or Canadian Pacific Lymphoma months.

New advances in the treatment of lymphoma have widened the range of available drugs and introduced a number of challenges. The need for a more precise treatment regimen is becoming more urgent however, the current prognostic tools only provide diagnosis. Predictive biomarkers to guide the choice of therapy during relapse remain elusive.

Duvelisib monotherapy was recently proven to be a successful treatment for patients suffering from relapsed or refractory peripheral T-cell lymphoma in the phase III SCHOLAR study, which involved 446 patients. Each contributing group abstracted patient-level data by using criteria defined in the research proposal and, in some cases, by a standardized, investigator-developed data entry form; this was then submitted to a central database for a pooled analysis by Kite Pharma.

Prognosis

Many people who suffer from lymphoma have been treated with chemotherapy and other treatments. The prognosis of each patient based on the type of lymphoma and how far the cancer has spread when diagnosed.

Burkitt's Lymphoma, for example, is a very aggressive cancer that could cause death due to its rapid growth and spread into other organs. It usually affects children in Africa and people with human immunodeficiency virus (HIV) infection as well as transplant recipients. It responds to standard combinations of chemotherapy. But other kinds of lymphoma that don't respond to standard chemotherapy may be extremely difficult to treat, including composite lymphoma that includes follicular-type non-follicular type tumors and indolent ones.

Researchers are now exploring new treatments that target specific areas in lymphoma, or modify the immune systems to aid the body in fighting the disease. This exciting era of basic science discoveries could bring better outcomes to even more patients. Researchers are working on CAR-T-cell therapy as an early treatment before the patient exhausts all other options, and may need the use of stem cells. Early results of the first trial, which utilizes the patient's immune system to kill cancer, revealed that the survival rate without event increased.